Literature DB >> 23727916

Expression and secretion of cholera toxin B subunit in lactobacilli.

Takahiro Okuno1, Nobuhiro Kashige, Tomomitsu Satho, Keiichi Irie, Yukihiro Hiramatsu, Tanjina Sharmin, Yuki Fukumitsu, Saori Uyeda, Seitaro Yamada, Tetsuya Harakuni, Takeshi Miyata, Takeshi Arakawa, Masumi Imoto, Akihisa Toda, Yukihiko Nakashima, Fumio Miake.   

Abstract

Lactic acid bacteria (LAB) are used in various fields, including in food and medical supplies. There has been a great deal of research into vaccine development using LAB as carriers due to their "generally recognized as safe" status. Cholera is an infectious disease that causes diarrhea due to cholera toxin (CT) produced by Vibrio cholerae. The pentameric cholera toxin B (CTB) subunit has no toxicity, and is used as an antigen in cholera vaccines and as a delivery molecule in vaccines to various diseases. In this study, we generated recombinant LAB expressing and secreting CTB. Here, we first report that CTB expressed and secreted from LAB bound to GM1 ganglioside. The secreted CTB was purified, and its immunogenicity was determined by intranasal administration into mice. The results of the present study suggested that it may be useful as the basis of a new oral cholera vaccine combining LAB and CTB.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23727916     DOI: 10.1248/bpb.b12-01021

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  10 in total

Review 1.  Peptide-Based Vaccines for Tuberculosis.

Authors:  Wenping Gong; Chao Pan; Peng Cheng; Jie Wang; Guangyu Zhao; Xueqiong Wu
Journal:  Front Immunol       Date:  2022-01-31       Impact factor: 7.561

Review 2.  Prophylactic vaccine delivery systems against epidemic infectious diseases.

Authors:  Chao Pan; Hua Yue; Li Zhu; Guang-Hui Ma; Heng-Liang Wang
Journal:  Adv Drug Deliv Rev       Date:  2021-07-17       Impact factor: 17.873

Review 3.  Cholera Toxin Subunit B as Adjuvant--An Accelerator in Protective Immunity and a Break in Autoimmunity.

Authors:  Thomas Stratmann
Journal:  Vaccines (Basel)       Date:  2015-07-24

Review 4.  Cholera toxin B: one subunit with many pharmaceutical applications.

Authors:  Keegan J Baldauf; Joshua M Royal; Krystal Teasley Hamorsky; Nobuyuki Matoba
Journal:  Toxins (Basel)       Date:  2015-03-20       Impact factor: 4.546

Review 5.  Formulation technologies for oral vaccines.

Authors:  R R C New
Journal:  Clin Exp Immunol       Date:  2019-08-08       Impact factor: 4.330

Review 6.  Long-Term Kinetics of Serological Antibodies against Vibrio cholerae Following a Clinical Cholera Case: A Systematic Review and Meta-Analysis.

Authors:  Basilua Andre Muzembo; Kei Kitahara; Debmalya Mitra; Ayumu Ohno; Shin-Ichi Miyoshi
Journal:  Int J Environ Res Public Health       Date:  2022-06-10       Impact factor: 4.614

7.  Recombinant fusion protein of cholera toxin B subunit with YVAD secreted by Lactobacillus casei inhibits lipopolysaccharide-induced caspase-1 activation and subsequent IL-1 beta secretion in Caco-2 cells.

Authors:  Yukihiro Hiramatsu; Masatatsu Yamamoto; Tomomitsu Satho; Keiichi Irie; Akiko Kai; Saori Uyeda; Yuki Fukumitsu; Akihisa Toda; Takeshi Miyata; Fumio Miake; Takeshi Arakawa; Nobuhiro Kashige
Journal:  BMC Biotechnol       Date:  2014-05-10       Impact factor: 2.563

8.  Subchronic Oral Dose Toxicity Study of Enterococcus Faecalis 2001 (EF 2001) in Mice.

Authors:  Yeun-Hwa Gu; Takenori Yamasita; Ki-Mun Kang
Journal:  Toxicol Res       Date:  2018-01-15

Review 9.  Lactobacillus Mucosal Vaccine Vectors: Immune Responses against Bacterial and Viral Antigens.

Authors:  Jonathan S LeCureux; Gregg A Dean
Journal:  mSphere       Date:  2018-05-16       Impact factor: 4.389

Review 10.  Adjuvant Strategies for Lactic Acid Bacterial Mucosal Vaccines.

Authors:  Allison C Vilander; Gregg A Dean
Journal:  Vaccines (Basel)       Date:  2019-10-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.